Overall, treatment was well tolerated; however, eGFR initially decreased by more than 30% in patient 2 with a NPHS2 plus INF2-variant as underlying cause of FSGS; as a consequence, blood pressure medication with a calcium antagonist was reduced. Here, INF2 is linked to focal segmental glomerulosclerosis.